Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring-Reference-Cited by-同舟云学术

Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring

Published:2020-07-01 Issue:1 Volume:72 Page:
ISSN:2090-911X
Container-title:The Egyptian Heart Journal
language:en
Short-container-title:Egypt Heart J

Author:

El Missiri Ahmed Mohamed^ORCID,Rayan Mona Mostafa,Awad Mohamed Medhat,El Desoky Ahmed Ibrahim

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s43044-020-00070-4.pdf

Reference25 articles.

1. Messina J, Humphreys I, Flaxman A et al (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:77–87

2. Manns MP, Buti M, Gane E et al (2017) Hepatitis C virus infection. Nat Rev Dis Primers 3:17006

3. Petta S, Maida M, Macaluso F et al (2016) Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 150:145–155

4. Manns MP, von Hahn T (2013) Novel therapies for hepatitis C—one pill fits all? Nat Rev Drug Discov 12(8):595–610

5. Sherman R, Li J, Shapley S et al (2013) Expediting drug development—the FDA’s new “breakthrough therapy” designation. N Engl J Med 369:1877–1880

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac effects of direct anti-viral treatment in type II diabetic patients with hepatitis C infection;BMC Cardiovascular Disorders;2024-07-08

2. Cardiovascular Risk Assessment after Sofosbuvir and Daclatasvir Regimen for Chronic Hepatitis C Virus Infection;Journal of the Pakistan Medical Association;2023-05-25

3. Profiling the physiological pitfalls of anti‐hepatitis C direct‐acting agents in budding yeast;Microbial Biotechnology;2021-08-11

4. The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction;Global Heart;2021